HTGF | High-Tech Gruenderfonds
High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Top Stages
Past deals in Medical
mo:re
Seed Round in 2025
Mo:re specializes in developing a three-dimensional cell robotic platform designed to automate medical research. Its platform aims to standardize cell culture workflows for drug development, enabling researchers to scale up experiments while maintaining traceability and quality.
Hema.to
Seed Round in 2025
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Lindis Blood Care
Venture Round in 2024
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Refoxy Pharma
Seed Round in 2024
Refoxy Pharma develops therapeutic medicines intended to treat age-related diseases and promote healthy longevity. It researches proteins that regulate multiple genes involved in stress resistance and metabolism and develops novel modulators of a central stress response pathway to influence aging through genetics, with the aim of extending the years of healthy living for patients.
Doctorflix
Seed Round in 2024
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.
Mediaire
Venture Round in 2024
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Aignostics
Series B in 2024
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
BIOVOX
Seed Round in 2024
BIOVOX develops sustainable plastic materials tailored for healthcare applications. Their compounds are renewable, degradable, recyclable, and offer rigidity, surface hardness, and transparency, enabling medical manufacturers to reduce environmental impact while maintaining high safety standards.
Symphera
Seed Round in 2024
Symphera is a developer of an innovative surgical system focused on enhancing the efficiency of minimally invasive procedures. The company specializes in a laparoscopic surgical tool that aims to radically simplify and expedite surgical processes. By prioritizing control, autonomy, safety, and efficiency, Symphera enables healthcare providers to perform surgeries with greater precision and effectiveness. Through its all-in-one surgical system, the company is committed to transforming the landscape of surgical practices, making advanced medical techniques more accessible and streamlined for both practitioners and patients.
IRUBIS
Seed Round in 2024
Founded in Munich, Germany in 2017, IRUBIS specializes in manufacturing Mid-Infrared (MIR) spectrometers and Attenuated Total Reflection (ATR) crystals. The company combines semiconductor technology with infrared spectroscopy to develop devices for analyzing protein-based drugs. IRUBIS offers a real-time bioprocess monitoring system using MIR spectroscopy, which measures glucose and lactate online without contamination risk. They also provide ATR crystals and accessory solutions.
HepaRegenix
Series C in 2024
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
SciRhom
Series A in 2024
SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.
CustomSurg
Seed Round in 2024
CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.
Tubulis
Series B in 2024
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
RAYDIAX
Seed Round in 2023
RAYDIAX is a manufacturer of advanced therapy-assist computed tomography (CT) systems aimed at enhancing the quality of minimally invasive medical interventions, particularly for tumor treatments. The company develops imaging solutions that integrate a navigation system with both 2D and 3D X-ray live imaging, enabling healthcare providers to perform procedures with greater safety and efficiency. RAYDIAX's technology is designed to reduce the risk of postoperative complications, ultimately resulting in shorter hospital stays and quicker recovery times for patients. Through its innovative approach, RAYDIAX seeks to improve outcomes for both patients and clinicians in the realm of cancer therapy.
Inovedis
Series A in 2023
Inovedis specializes in innovative medical technologies aimed at optimizing patient care while reducing time and costs within the healthcare sector. The company develops advanced surgical devices, such as its flagship product designed for treating shoulder injuries, which leverages science-based technology to enable anatomical reconstruction of physiological tendon-bone connections.
Kranus Health
Series A in 2023
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Doctorflix
Seed Round in 2023
Doctorflix is a medical education platform designed for healthcare professionals seeking to enhance their knowledge and skills in treatment methods. The platform focuses on simplifying and democratizing the exchange of medical knowledge by connecting doctors, hospitals, and pharmaceutical companies. It offers a diverse array of content, including on-demand videos, live events, articles, and podcasts, facilitating the transformation of theoretical knowledge into practical applications. With a commitment to advancing professional development, Doctorflix aims to accelerate the continuing education of medical professionals worldwide, leveraging its expertise in both the medical and technological sectors to deliver effective training solutions.
smartbax
Seed Round in 2023
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
Hema.to
Seed Round in 2023
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Nia Health
Seed Round in 2023
Nia Health develops digital health applications focused on dermatological conditions like eczema and psoriasis. Its AI-powered app provides personalized support and relief, aiming to improve patient outcomes through innovative digital solutions.
Dualyx
Series A in 2023
Dualyx is a biotechnology company focused on the discovery and development of biological therapies aimed at treating autoimmune and rare diseases. The company specializes in the creation of immune modulators, particularly Treg-targeted therapies, which are designed to suppress undesirable autoimmune responses in patients. Through its innovative approach, Dualyx aims to provide lasting treatments that offer potential cures for those suffering from autoimmune conditions.
Phialogics
Pre Seed Round in 2023
Phialogics is a biotechnology company focused on developing innovative biologics to regulate the immune response in both acute and chronic inflammation. Its platform enables the creation of engineered antibodies and cell-type-specific immune checkpoint activators, targeting autoimmune diseases such as lupus, type 1 diabetes, and rheumatoid arthritis.
Mosanna Therapeutics
Seed Round in 2023
Mosanna Therapeutics is a biotechnology company based in Basel that focuses on improving patient outcomes and quality of life for individuals with high unmet medical needs. The company employs a precision medicine approach, specializing in the development of medicinal nasal sprays. Mosanna carefully selects innovative medicines for further development and collaborates with leading contract research organizations to ensure expertise in specialized fields. This strategy enables hospitals and doctors to effectively treat patients suffering from various diseases.
Mbiomics
Series A in 2023
Mbiomics is a biotechnology company focused on transforming microbiome research, diagnostics, and therapeutics. The firm operates a high-throughput, low-cost platform designed for dynamic and real-time analysis and quantification of the human gut microbiome. This technology enables precise diagnostics and targeted therapies, aiming to enhance patients' lives through innovative approaches to health management.
hbox
Seed Round in 2023
HBOX Therapies is a developer of technology that facilitates the lung-protective treatment of respiratory patients. They produce miniaturized hyperoxygenation therapies. The technology's application is miniature respiratory assistance for patients suffering from lung failure.
PraxisEins.
Pre Seed Round in 2023
PraxisEins is a healthcare startup focused on enhancing outpatient care through innovative technology. The company develops a software-enabled platform that assists physicians in digitizing their processes, ultimately aimed at improving patient care and alleviating administrative burdens. By leveraging modern technology, PraxisEins enables doctors to conduct same-day consultations with patients, addressing the supply vacuum in outpatient services. Through its solutions, the company seeks to streamline workflows for healthcare providers and enhance the overall efficiency of outpatient care.
FundaMental Pharma
Seed Round in 2022
FundaMental Pharma is a neuroscience company developing novel drugs targeting neurodegeneration. Its portfolio focuses on preclinical stage therapies designed to uncouple the physiological function of glutamate-gated NMDA receptors from their toxic effects, aiming to stop neurodegeneration and improve brain health.
neotiv
Seed Round in 2022
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.
Resolve BioSciences
Series B in 2022
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.
IRUBIS
Seed Round in 2022
Founded in Munich, Germany in 2017, IRUBIS specializes in manufacturing Mid-Infrared (MIR) spectrometers and Attenuated Total Reflection (ATR) crystals. The company combines semiconductor technology with infrared spectroscopy to develop devices for analyzing protein-based drugs. IRUBIS offers a real-time bioprocess monitoring system using MIR spectroscopy, which measures glucose and lactate online without contamination risk. They also provide ATR crystals and accessory solutions.
Kupando
Series A in 2022
Kupando is a biopharmaceutical company focused on developing immunostimulatory agents targeting toll-like receptors. Its mission is to create affordable immunotherapy options for cancer patients and prevent infectious diseases.
Aignostics
Series A in 2022
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
Kranus Health
Series A in 2022
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Noscendo
Venture Round in 2022
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.
Tubulis
Series B in 2022
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Ebenbuild
Seed Round in 2022
Ebenbuild is a technology company that specializes in developing and commercializing advanced health tech solutions focused on respiratory diseases. Building on two decades of research from TU Munich, the company employs lung simulation models to create a versatile platform with applications in both drug development and healthcare. One of its key innovations is a digital trials application that enhances drug delivery predictions, thereby accelerating the drug development process for Biotech, Pharma, and MedTech companies. This application allows for the optimization of delivery parameters before clinical trials, thus increasing success rates. Additionally, Ebenbuild's healthcare application integrates with hospital IT systems to provide actionable intelligence at the patient's bedside. It focuses on personalizing mechanical ventilation for patients with Acute Respiratory Distress Syndrome, significantly improving their prognosis. By continuously expanding its platform to address various indications, Ebenbuild aims to enhance patient outcomes while supporting medical staff and healthcare systems.
Lindis Blood Care
Venture Round in 2022
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Ceregate
Series A in 2022
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company focuses on developing a computer-brain interface (CBI) technology that enhances the programming of neuromodulation systems. This innovative platform allows for the direct transmission of information into human consciousness, utilizing existing neuromodulation implants to improve medical treatments. CereGate's technology aims to support patients with neurological disorders or sensory deficits by providing new therapeutic options that enable them to adapt and enhance their conditions independently. The company's approach encompasses a broad range of applications, from sensory substitution to gait improvement.
Newsenselab (M-sense)
Seed Round in 2021
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Emergence Therapeutics
Series A in 2021
Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing innovative antibody-drug conjugates (ADCs) to address high-need cancers. Established in 2019, the company leverages advanced technologies in antibody design, linker systems, and therapeutic payloads to create targeted treatments. Its lead program specifically targets Nectin-4, a clinically validated marker for various cancers, utilizing a highly specific antibody in combination with optimized linker technology and amanitin as the payload. This approach aims to provide effective therapeutic options for challenging cancer types. Emergence Therapeutics is also exploring opportunities to develop additional first- or best-in-class ADCs to meet unmet medical needs in oncology.
Qnami
Series A in 2021
Qnami AG is a Swiss company that specializes in the development of quantum sensing technologies for non-invasive magnetic imaging at the nanoscale. Founded in 2017 and based in Basel, Qnami's flagship products include the ProteusQ, a magnetic imaging microscope, and the Quantum Diamond, which features diamond probes with a single nitrogen-vacancy center for high-resolution imaging. These technologies allow for advanced applications in various fields, including multiferroic antiferromagnets, magnetic random-access memory (MRAM), and superconductivity. By enabling researchers and industries to measure electric and magnetic fields with exceptional sensitivity, Qnami enhances the capabilities of imaging techniques and supports groundbreaking scientific studies and industrial advancements.
PreComb
Seed Round in 2021
PreComb develops advanced technologies to adapt cancer therapies to individual patients, aiming to enhance treatment success rates and improve patient outcomes.
GeneQuine Biotherapeutics
Series A in 2021
Founded in 2011, GeneQuine Biotherapeutics specializes in designing and developing gene therapies for clients. Its primary focus is on treating osteoarthritis through innovative products such as GQ-201, GQ-202, and GQ-203.
Kranus Health
Seed Round in 2021
Kranus Health is a global leader in virtual care for urology. It focuses on developing and providing clinically validated therapies for various urological conditions, ranging from andrology to uro-oncology.
Mediaire
Seed Round in 2020
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Resolve BioSciences
Series A in 2020
Resolve BioSciences GmbH, founded in 2016 and based in Monheim am Rhein, Germany, specializes in spatial multiomics analysis platforms that enhance the understanding of single-cell spatial biology. The company's innovative technology enables researchers to obtain high-resolution spatial views of subcellular gene expression activities. Resolve BioSciences offers a range of services that encompass bioinformatics, imaging, genomics, transcriptomics, histology, and pathology, among others. Their expertise extends to various fields, including neuroscience, oncology, infectious diseases, and agrigenomics, facilitating advanced studies in cell atlasing and single-cell analysis.
heartbeat medical
Series A in 2020
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Ceregate
Series A in 2020
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company focuses on developing a computer-brain interface (CBI) technology that enhances the programming of neuromodulation systems. This innovative platform allows for the direct transmission of information into human consciousness, utilizing existing neuromodulation implants to improve medical treatments. CereGate's technology aims to support patients with neurological disorders or sensory deficits by providing new therapeutic options that enable them to adapt and enhance their conditions independently. The company's approach encompasses a broad range of applications, from sensory substitution to gait improvement.
Aignostics
Seed Round in 2020
Founded in 2018, Aignostics develops AI-powered diagnostics and pathology software solutions for pharmaceutical research and clinical applications. Its explainable AI overcomes the limitations of conventional 'black-box' AI by providing precise heatmaps and image overlays, enabling pathologists to verify results quickly.
Atriva Therapeutics
Debt Financing in 2020
Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.
stimOS
Series A in 2020
stimOS GmbH is a biotechnology company based in Constance, Germany, founded in 2015. The company specializes in developing innovative drug delivery biochemical procedures aimed at enhancing bone formation, inflammation reduction, and healing processes. stimOS focuses on refining, functionalizing, and activating implant materials, transforming them into interfaces that closely mimic natural bone. By providing advanced technologies and procedures, stimOS serves as a supplier and service provider to implant manufacturers, facilitating the development of improved implant surfaces. The company's solutions are designed to promote early and healthy bone integration, thereby enabling faster recovery and improved outcomes for patients undergoing surgical procedures.
Tubulis
Series A in 2020
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.
Kumovis
Series A in 2020
Kumovis is a medical technology company that specializes in developing a 3D printing system designed for both industrial and medical applications. The company focuses on the processing of high-performance polymers to create patient-customized implants. By integrating clean room technology into its 3D printing solutions, Kumovis enables hospitals to perform medical operations more conveniently and effectively, enhancing the overall quality of care.
Noscendo
Series A in 2020
Noscendo GmbH is a diagnostics company based in Duisburg, Germany, focused on the development of bioinformatics solutions for identifying and assessing pathogens associated with bloodstream infections. Utilizing Next Generation Sequencing technology, Noscendo's platform offers a hypothesis-free approach to detect a wide range of infection-causing microbes, including bacteria, fungi, DNA viruses, and parasites, from a single standard blood draw. This innovative method eliminates the need for prior cultivation or specific knowledge about the infection's nature, empowering intensive care clinicians to make accurate distinctions between commensals, contamination, and genuine infections. Through its proprietary algorithms, Noscendo enhances the identification process, ultimately aiming to improve patient outcomes in critical care settings.
iATROS
Seed Round in 2020
iATROS GmbH is a Munich-based company founded in 2019 that specializes in developing a mobile application and platform aimed at enhancing the care of cardiology patients. The platform connects patients with medical caregivers and offers a range of services, including therapy and medication planning, progress tracking, ECG diagnosis, and the maintenance of blood pressure and sugar databases. It also facilitates consultations with physicians and enables the secure storage of health data. As the prevalence of cardiovascular diseases increases, iATROS aims to improve the lives of both chronic and acute patients while addressing the significant healthcare costs associated with these conditions. By leveraging smart health trackers, vital data collection, and advanced AI analytics, the company enhances treatment outcomes and provides patients with 24/7 access to healthcare professionals, ensuring they feel safe in managing their conditions.
Scipio Bioscience
Series A in 2020
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.
Ceregate
Venture Round in 2020
CereGate GmbH is a brain-machine interface company based in Hamburg, Germany, with an additional office in San Diego, California. Founded in 2019, the company focuses on developing a computer-brain interface (CBI) technology that enhances the programming of neuromodulation systems. This innovative platform allows for the direct transmission of information into human consciousness, utilizing existing neuromodulation implants to improve medical treatments. CereGate's technology aims to support patients with neurological disorders or sensory deficits by providing new therapeutic options that enable them to adapt and enhance their conditions independently. The company's approach encompasses a broad range of applications, from sensory substitution to gait improvement.
HepaRegenix
Series B in 2020
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
Mecuris
Series B in 2020
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.
Lindis Blood Care
Venture Round in 2019
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Verovaccines
Seed Round in 2019
VEROVACCiNES GmbH is a biopharmaceutical company based in Halle, Germany, founded in 2017 as a spin-off from the Martin Luther University Halle-Wittenberg. The company specializes in developing innovative vaccine solutions to protect animals from infectious diseases, utilizing a unique yeast-based technology to create subunit marker vaccines. This approach has been validated through proof-of-concept studies demonstrating protection across various animal species against several viral diseases. VEROVACCiNES has acquired intellectual property, branding, and expertise from a previous project funded by the BMBF GO-Bio program and is eligible for additional funding. The company actively collaborates with veterinary pharmaceutical firms, universities, and research institutions to enhance its vaccine development efforts.
Newsenselab (M-sense)
Seed Round in 2019
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Qnami
Seed Round in 2019
Qnami AG is a Swiss company that specializes in the development of quantum sensing technologies for non-invasive magnetic imaging at the nanoscale. Founded in 2017 and based in Basel, Qnami's flagship products include the ProteusQ, a magnetic imaging microscope, and the Quantum Diamond, which features diamond probes with a single nitrogen-vacancy center for high-resolution imaging. These technologies allow for advanced applications in various fields, including multiferroic antiferromagnets, magnetic random-access memory (MRAM), and superconductivity. By enabling researchers and industries to measure electric and magnetic fields with exceptional sensitivity, Qnami enhances the capabilities of imaging techniques and supports groundbreaking scientific studies and industrial advancements.
Draupnir Bio
Seed Round in 2019
Draupnir Bio is a biotechnology company focused on developing a new class of cholesterol-lowering medicines to prevent heart blood clots more effectively than existing therapies. The company pursues a platform that maps and leverages the glycome to build heparan sulfate glycomimetics, enabling synthesis, screening, and selection of potent, specific drug candidates for cardiovascular, inflammatory, and infectious diseases. Leveraging its technology, the firm aims to develop protein degraders that target extracellular disease proteins, potentially broadening therapeutic reach across unmet medical needs. The approach seeks to offer convenient treatment options that could reduce reliance on traditional injectables. Through its glycome-based platform, Draupnir Bio targets modalities beyond small molecules, with a focus on extracellular targets and biologics-compatible strategies to improve patient outcomes.
Vacis
Venture Round in 2019
Vacis specializes in tissue engineering technology for creating body-own blood vessels. Its platform induces the body to form functional blood vessels, offering novel therapeutic options and reducing complications associated with prosthetic vascular grafts.
Tacalyx
Seed Round in 2019
Tacalyx GmbH is an oncology company based in Berlin, Germany, dedicated to the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies for cancer treatment. As a spin-off from the Max-Planck-Institute of Colloids and Interfaces, the company leverages advanced carbohydrate synthesis technology to produce highly pure TACA structures. These structures serve as novel targets for cancer therapies, addressing the tumor-specific expression of TACAs that results from aberrant glycosylation, which is linked to cancer progression, including metastasis and immune system suppression. Tacalyx aims to develop innovative therapeutics that enhance the effectiveness of immunotherapies by triggering robust anti-cancer responses through the synthesis and identification of antibodies targeting these carbohydrate antigens.
Belyntic
Seed Round in 2019
Belyntic is a biotechnology company focused on developing innovative vaccines aimed at preventing viral diseases, bacterial infections, and cancer. The company has created a cutting-edge platform that utilizes self-adjuvant synthetic long peptides to effectively induce cellular immunity. By offering ready-to-use research kit packages and engineered vaccines, Belyntic activates T-cell immune responses, providing significant potential for advancing protective measures against various health threats. Additionally, the company integrates artificial intelligence to enhance its vaccine development, allowing for the incorporation of pathogen-specific epitopes into a self-adjuvant nano vaccine structure. This approach facilitates research, development, and production of novel peptide therapeutics, contributing to healthier lives.
miRdetect
Seed Round in 2019
miRdetect GmbH is a German biotechnology company based in Bremen, established in 2016. The company develops and markets in-vitro diagnostic tests, focusing on the early detection and diagnosis of cancer. Among its products is the miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect employs advanced molecular biological techniques that enable the precise identification of minute quantities of nucleic acids, facilitating accurate cancer diagnosis. In addition to its current offerings, the company is actively engaged in research and development to create new diagnostic tests aimed at improving cancer detection capabilities.
NAVAN Technologies
Seed Round in 2019
NAVAN Technologies, Inc. is a pre-clinical stage biotechnology company based in South San Francisco, California, founded in 2016. The company specializes in developing and commercializing its proprietary NanoStraw platform technology, which provides a direct and gentle means of accessing the cytosol of cells. This innovative platform addresses a significant challenge in the field of cell and gene therapies by enabling the efficient delivery of various cargoes into difficult-to-transfect cells without causing disruption. NAVAN's technology aims to enhance the capabilities of researchers and improve the effectiveness of therapeutic applications in biotechnology.
Mediaire
Seed Round in 2019
Mediaire GmbH is a Berlin-based company founded in 2018 that specializes in software solutions for medical imaging. Its flagship application, md.Brain, focuses on quantitative brain volumetry, facilitating early detection of senile dementia and the automated measurement of medullary lesions in multiple sclerosis patients. By leveraging artificial intelligence, Mediaire enhances the workflow of radiologists through efficient image analysis, providing precise examination results and diagnostic suggestions. The software is designed to improve both the quality and speed of diagnostic and therapeutic procedures, making it a valuable tool for healthcare centers and radiologists.
Cytena
Series A in 2019
Cytena develops a laboratory device for separating and printing single cells. Its core product, the cy-Clone, encapsulates cells in droplets for gentle delivery onto substrates, ensuring high cell viability and minimal risk of cross-contamination. This technology aids in drug development, cancer research, and stem cell analysis.
Mecuris
Series A in 2019
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.
Atriva Therapeutics
Series A in 2019
Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.
Preomics
Series A in 2018
PreOmics GmbH is a biotechnology company based in Planegg, Germany, specializing in mass spectrometry (MS)-based proteomics. Founded in 2016 as a spin-off from the Max-Planck Institute of Biochemistry, PreOmics develops innovative tools and technologies aimed at enhancing protein analysis for researchers worldwide. The company's flagship product, the iST Kit, facilitates rapid and reproducible preparation of peptide mixtures from various starting materials, streamlining the sample preparation process within just one hour. PreOmics also offers high-throughput processing accessories and a robust platform that leverages liquid chromatography coupled with mass spectrometry to enable comprehensive protein identification, quantification, and analysis of post-translational modifications. Through its advanced solutions, PreOmics supports the scientific community in accelerating discovery and understanding of protein interactions and functions.
denovoMATRIX
Seed Round in 2018
Founded in 2018, denovoMATRIX develops biomimetic coatings for stem cell culture. Its products include screenMATRIX, which enhances cell adhesion and differentiation, and myMATRIX, a custom-coated tissue cultureware for serum-free media. These are used in stem cell research, tissue models, and cell-based therapies.
Amal Therapeutics
Series B in 2018
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
OMEICOS Therapeutics
Series C in 2018
OMEICOS Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics to prevent and treat cardiovascular and ophthalmic diseases. The company uses synthetic analogues of Epoxyeicosanoids, metabolites of omega-3 fatty acids, to activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells. Its approach leverages endogenous cardio-protective signaling to stabilize heart rhythm and potentially mitigate electrical and structural remodeling of diseased myocardium.
Kumovis
Seed Round in 2018
Kumovis is a medical technology company that specializes in developing a 3D printing system designed for both industrial and medical applications. The company focuses on the processing of high-performance polymers to create patient-customized implants. By integrating clean room technology into its 3D printing solutions, Kumovis enables hospitals to perform medical operations more conveniently and effectively, enhancing the overall quality of care.
Newsenselab (M-sense)
Venture Round in 2018
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
neotiv
Seed Round in 2018
Neotiv GmbH is a German company founded in 2017 and headquartered in Magdeburg, specializing in the development of mobile software aimed at monitoring and enhancing memory functions. The company creates digital solutions that facilitate the early detection and ongoing tracking of memory problems, particularly those associated with aging and early stages of Alzheimer’s disease. Neotiv's offerings include memory tests that focus on brain regions affected by cognitive decline, while also providing insights derived from scientific research to support users in managing their cognitive health. The application is designed not only for individual users but also serves as a valuable tool for healthcare professionals and drug developers, enabling them to monitor psychological effects and assist patients with dementia.
heartbeat medical
Venture Round in 2017
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
Scipio Bioscience
Seed Round in 2017
Scipio Bioscience SAS is a biotechnology company based in Paris, France, founded in 2017. It specializes in manufacturing benchtop kits that provide innovative sample preparation solutions for single-cell studies. These kits are designed for use in sequencing applications across both clinical and basic research, with a particular focus on transcriptomics. Scipio Bioscience's products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating more precise and efficient analysis in various scientific investigations.
RIMASYS
Venture Round in 2017
RIMASYS is dedicated to advancing surgical education and medical technology research and development. The company focuses on creating realistic fractures in human specimens through a unique algorithm and device, which supports practical skill training for surgeons. By integrating digital learning, virtual reality, and 3D printing, RIMASYS aims to improve patient outcomes and enhance the quality of life for individuals requiring advanced therapies and operations. Their innovative approach facilitates collaboration among medical science, academia, and industry, fostering the development of better implants and surgical techniques.
Amal Therapeutics
Series B in 2017
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
stimOS
Seed Round in 2017
stimOS GmbH is a biotechnology company based in Constance, Germany, founded in 2015. The company specializes in developing innovative drug delivery biochemical procedures aimed at enhancing bone formation, inflammation reduction, and healing processes. stimOS focuses on refining, functionalizing, and activating implant materials, transforming them into interfaces that closely mimic natural bone. By providing advanced technologies and procedures, stimOS serves as a supplier and service provider to implant manufacturers, facilitating the development of improved implant surfaces. The company's solutions are designed to promote early and healthy bone integration, thereby enabling faster recovery and improved outcomes for patients undergoing surgical procedures.
Atriva Therapeutics
Seed Round in 2017
Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.
SciRhom
Seed Round in 2017
SciRhom GmbH is a biotechnology company focused on the preclinical and early clinical development of innovative biopharmaceuticals aimed at treating life-threatening autoimmune diseases. Established in 2016 through a collaboration between experienced academic and industry scientists, the company leverages extensive research and a robust network of experts in antibody development. SciRhom specializes in creating therapeutic antibodies targeting iRhom2, a significant modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. This focus allows the company to develop improved treatment options that enhance the protection of skin and intestinal barriers, ultimately benefiting patients suffering from serious autoimmune conditions.
HepaRegenix
Series A in 2016
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.
AudioCure Pharma
Series A in 2016
AudioCure Pharma GmbH is a pharmaceutical company based in Berlin, Germany, specializing in the development of drugs for neurodegenerative diseases and hearing impairments. Founded in 2010 by Professor Hans Rommelspacher, the company has assembled a team of skilled scientists and executives, supported by a network of academic partners and strategic investors. AudioCure Pharma is located in a central area of Mitte, providing access to numerous high-tech companies and universities, including close ties with the Charité University. The company is focused on advancing its leading compound, AC102, which is in late-stage preclinical development for treating acute noise-induced hearing loss and has demonstrated preclinical proof of concept since 2016.
Newsenselab (M-sense)
Venture Round in 2016
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Mecuris
Seed Round in 2016
Mecuris GmbH, founded in 2016 and based in Munich, Germany, specializes in the development and supply of customized orthopedic aids. The company's product range includes orthoses, prostheses, and related equipment, with notable offerings such as Mecuris FirStep, Mecuris NexStep, Mecuris cover, and the Mecuris Solution Platform. Mecuris aims to revolutionize the orthotics and prosthetics (O&P) industry by leveraging digital technology and 3D printing. Their platform uses patient data and scans to semi-automatically create individualized 3D designs for patient aids, which can be printed locally. This approach significantly reduces production times, enabling a fully customized fit, functionality, and appearance for wearers. Mecuris collaborates with O&P professionals to co-create these custom products, enhancing the lives of patients through innovative digital solutions.
CryoTherapeutics
Series B in 2016
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in the development of a proprietary cryotherapy system aimed at treating coronary artery disease, a major cause of heart attacks. The company focuses on demonstrating the clinical benefits and ensuring the safety and efficacy of cryoenergy in the cardiovascular system. Its novel catheter system utilizes cryo energy to treat and prevent heart attacks, offering a promising approach to addressing the challenges posed by diseased coronary arteries. Through its early-stage commercialization efforts, CryoTherapeutics aims to enhance treatment options for heart surgeons and improve patient outcomes in cardiovascular health.
Bentekk
Seed Round in 2016
Bentekk GmbH, founded in 2014 and based in Hamburg, Germany, specializes in the development and manufacturing of intelligent gas measuring systems designed for on-site analysis of contaminants. The company focuses on portable gas measurement devices that utilize gas chromatography and photo ionization detection to accurately assess volatile organic compounds and other hazardous substances. This technology is applicable across various sectors, including environmental monitoring, first response, logistics, life sciences, and the chemical industry. By providing equipment that enhances occupational health and safety, Bentekk enables better monitoring of toxic gas levels, contributing to safer working environments. As a subsidiary of Dräger Safety AG & Co. KGaA since 2017, Bentekk continues to advance its mission of improving workplace safety through innovative measurement solutions.
Amal Therapeutics
Series A in 2016
Founded in 2012, Amal Therapeutics is a Swiss biotechnology company focused on developing therapeutic vaccines for oncology using its proprietary cell penetrating peptide platform. Its vaccines aim to activate killer T cells and promote immunological memory, facilitating effective cancer treatment.
Abviris Deutschland
Seed Round in 2016
Abviris Deutschland GmbH is a German company founded in 2014, specializing in the development, manufacture, and marketing of in-vitro diagnostics and medical devices aimed at addressing oral cancer. Based in Ammersbek, the company focuses on utilizing immunologically active components, including a variety of antibodies targeting different types of human papilloma virus (HPV) and relevant antigens. One of its key products is PrevO-Check, an in-vitro diagnostic medical device designed for the screening of HPV-induced oral cavity cancer. Abviris Deutschland addresses the challenge of early detection, particularly since HPV infections often do not exhibit early symptoms, leading to late-stage diagnoses. The company's innovations aim to improve screening processes, especially in areas of the oral cavity that are not typically examined during standard dental visits.
heartbeat medical
Venture Round in 2016
Heartbeat Medical develops a healthcare platform focused on tracking patient-reported outcomes. The platform serves as a comprehensive patient management tool suitable for healthcare facilities of all sizes. By emphasizing the importance of quality of life data, Heartbeat Medical enables healthcare providers to gain valuable insights through intelligent evaluations of diagnostics and treatment methods. This approach allows physicians and therapists to enhance their understanding of patient experiences and improve treatment strategies based on real-world evidence.
LifeTime
Seed Round in 2016
LifeTime is a digital health application established by connected-health.eu GmbH in 2014, now operated by LifeTime GmbH since August 2019. The platform focuses on the secure digital transmission and decentralized management of medical data, facilitating efficient communication between healthcare providers and patients. LifeTime enables doctors and practice teams to digitally send medical findings, images, and other important documents, improving the accuracy and efficiency of healthcare delivery. By enhancing the understanding of health and treatment histories, LifeTime aims to streamline workflows for healthcare professionals while ensuring the secure handling of sensitive medical information.
Bomedus
Series B in 2015
Bomedus is a Germany-based medical device company founded in 2011, focused on improving mobility for individuals suffering from chronic back pain. The company develops innovative devices that utilize an electro-therapeutic method to provide permanent and sustainable pain reduction. By non-invasively modulating pathologically altered neuronal impulses, Bomedus aims to enhance the quality of life for patients dealing with pain-related challenges.
Cytena
Seed Round in 2015
Cytena develops a laboratory device for separating and printing single cells. Its core product, the cy-Clone, encapsulates cells in droplets for gentle delivery onto substrates, ensuring high cell viability and minimal risk of cross-contamination. This technology aids in drug development, cancer research, and stem cell analysis.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.